Phase II study of low dose suramin as a sensitizer of paclitaxel/carboplatin (P/C) in non small cell lung cancer (NSCLC)
Miguel A. Villalona‐Calero(University of California, Irvine), Jessie L.‐S. Au(Temple University Hospital), R. Jensen(National Cancer Institute), Keigo Kobayashi(Osaka Gakuin University), Teng‐Kuang Yeh(National Cancer Institute), Soo‐Chang Song(Bio-Medical Science (South Korea)), M. R. Grever(National Cancer Institute), Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Donn C. Young(The Ohio State University), G. Wientjes(National Cancer Institute)
Cited by 2
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k
Delivery of siRNA Therapeutics: Barriers and Carriers
|The AAPS Journal|2010|787
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537